Capabilities

From target validation to indication discovery, we generate the genetic evidence your program depends on. Every analysis is designed to inform a decision.

Tier 1

Foundational evidence

Validation

The essential evidence layer. Confirm, challenge, or redirect your program before you commit further capital or time.

Efficacy

Causal genetic evidence linking your target to your disease of interest, or revealing a stronger indication you hadn’t considered.

Safety

What does genetic perturbation of this target tell us about on- and off-target risk and safety liabilities? Know the biological profile before you commit to development.

Repurposing

Uncover unexpected therapeutic value. The same target may hold opportunity across multiple disease areas your team hasn’t yet explored.

Target Engagement

Molecular-level biomarkers that confirm your target is biologically active, genetic evidence that your mechanism is engaged in humans.

Tier 2

Deeper intelligence

Advanced Characterization

When the headline signal isn’t enough. We generate the genetic insight that directly informs clinical trial design, patient stratification, and regulatory strategy.

Heterogeneity Analysis

Does the genetic signal hold across sexes, ancestries, and age groups? We identify the differences that shape trial design, informing eligibility criteria, patient selection, and label strategy. Understanding where effects diverge is a clinical and commercial asset that cannot be surfaced from a headline association alone.

Interactive Effects

How does your target interact with other biological pathways? We map the genetic context of comorbidities, modifier effects, and pathway crosstalk, the mechanistic intelligence that informs inclusion criteria, combination therapy strategies, and the design of trials built to succeed.

Tier 3

Upstream intelligence

Discovery

No target yet? We work upstream, starting from your indication of interest and building the genetically supported target landscape from the ground up.

Start with an indication

Causal genetic evidence linking your target to your disease of interest, or revealing a stronger indication you hadn’t considered.

Choose the engagement that fits your question

Not every question requires the same depth. We offer three engagement formats so you get the right level of rigor for the decision at hand.

Short Evidence Reports

A focused genetic evidence report built around a clearly defined question. Best for a single target and indication, or for comparing multiple targets head-to-head. Fast turnaround, decision-ready output.

Extended Analytical Engagement

An extended analytical engagement for complex, multi-part questions. Mendelytics™ draws on large-scale population genomics and deep phenotyping resources, spanning hundreds of thousands of participants across diverse ancestries and healthcare settings, to deliver iterative, transparent evidence built around your program’s evolving needs.

Partnerships

Long-term embedded genetic intelligence across your portfolio or discovery program. Co-design, continuous analysis, and strategic scientific input, making genetics a sustained part of how you develop drugs.

1 target × 1 indication, or comparative across targets
Genetic evidence score included
Methodological transparency throughout
Typical turnaround: 2–4 weeks
Structured for go/no-go decisions
Outputs produced by Mendelytics™

Tier 1

Tier 2

Tier 1

Tier 2

Tier 3

Choose the engagement that fits your question

Not every question requires the same depth. We offer three engagement formats so you get the right level of rigor for the decision at hand.

Short Evidence Reports

1 target × 1 indication, or comparative across targets
Genetic evidence score included
Methodological transparency throughout
Typical turnaround: 2–4 weeks
Structured for go/no-go decisions
Outputs produced by Mendelytics™

Tier 1

Extended Analytical Engagement

Tier 1

Tier 2

Partnerships

Tier 1

Tier 2

Tier 3

Ask us about your targets

We'll bring the evidence Whether you have a specific asset in mind or want to understand how genetic intelligence could strengthen your program or portfolio – let’s talk.